Results: 2

1.
Figure 2

Figure 2. From: The VEGF family in cancer and antibody-based strategies for their inhibition.

Current anti-angiogenic mAbs with applications in cancer therapy. hz, humanized; hu, human; ms, mouse; rt, rat; fp, fusion protein; mCRC, metastatic colorectal cancer; NSCLC, non-small cell lung cancer; mBC, metastatic breast cancer; mRCC, metastatic renal cell carcinoma.

Laura A Sullivan, et al. MAbs. 2010 Mar-Apr;2(2):165-175.
2.
Figure 1

Figure 1. From: The VEGF family in cancer and antibody-based strategies for their inhibition.

Blockade of the VEGF pathway with mAbs. The specificity of the VEGF family ligands for the VEGF receptors and coreceptors are shown. The clinically-relevant mAbs targeting the anti-VEGF pathway discussed in this review are placed based on their blockade of VEGF ligand or receptor. The ligand-binding antibodies bevacizumab (bev), r84, and VEGF-Trap inhibit ligand binding to the indicated receptor. IMC-18F1 and IMC-1121B bind VEGFR1 and VEGFR2 respectively, and prevent ligand binding.

Laura A Sullivan, et al. MAbs. 2010 Mar-Apr;2(2):165-175.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk